
|Articles|August 1, 2002
Caspofungin adds to aspergillosis armamentarium
New Orleans - The novel antifungal agent caspofungin (Cancidas) is a helpful addition to the armamentarium of medications that are currently used to treat aspergillosis, according to Tamara Koss, M.D. It may be a particularly appropriate modality in immunocompromised patients who have not responded to conventional antimycotics, she said.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
2
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
3
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
4
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
5











